日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML

BRG1/BRM抑制剂联合BET抑制剂或地西他滨治疗高危MECOM重排急性髓系白血病疗效显著。

Fiskus, Warren; Mill, Christopher P; Piel, Jessica; Collins, Mike; Hentemann, Murphy; Cuglievan, Branko; Birdwell, Christine E; Das, Kaberi; Davis, John A; Hou, Hanxi; Jain, Antrix; Malovannaya, Anna; Flores, Lauren B; Kadia, Tapan M; Daver, Naval; Sasaki, Koji; Takahashi, Koichi; Hammond, Danielle; Wang, Jian; Loghavi, Sanam; Su, Xiaoping; DiNardo, Courtney D; Delwel, Ruud; Bhalla, Kapil N

Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies

维奈托克治疗相关非核心结合因子急性髓系白血病的疗效

Senapati, Jayastu; Croden, Jennifer; Garcia-Manero, Guillermo; Takahashi, Koichi; Daver, Naval G; Kadia, Tapan M; Borthakur, Gautam; Short, Nicholas James; Jabbour, Elias; Haddad, Fadi; Marvin-Peek, Jennifer; Abbas, Hussein A; Bose, Prithviraj; Tang, Guilin; Loghavi, Sanam; Shpall, Elizabeth J; Ramdial, Jeremy; Popat, Uday R; Champlin, Richard E; Ravandi, Farhad; Kantarjian, Hagop M; Dinardo, Courtney D

Beyond somatic mutations: the role of next-generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia

除了体细胞突变之外:下一代测序在识别急性髓系白血病患者种系易感性中的作用

Loghavi, Sanam; Ravandi, Farhad

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

一线去甲基化药物维奈托克联合FLT3抑制剂治疗FLT3突变型急性髓系白血病患者的长期疗效

Short, Nicholas J; Loghavi, Sanam; Yilmaz, Musa; Karrar, Omer; Kim, Kunhwa; Dinardo, Courtney D; Kadia, Tapan M; Maroun, Manuel; Borthakur, Gautam; Issa, Ghayas C; Jabbour, Joseph; Oran, Betul; Shpall, Elizabeth J; Popat, Uday; Patel, Keyur P; Routbort, Mark; Konopleva, Marina; Ravandi, Farhad; Kantarjian, Hagop; Daver, Naval

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML

对于不适合接受强化化疗的异柠檬酸脱氢酶突变型急性髓系白血病患者,一线三联疗法(包括去甲基化药物、维奈托克和异柠檬酸脱氢酶抑制剂)的疗效

DiNardo, Courtney D; Marvin-Peek, Jennifer; Loghavi, Sanam; Takahashi, Koichi; Issa, Ghayas C; Jen, Wei-Ying; Daver, Naval G; Reville, Patrick K; Short, Nicholas J; Sasaki, Koji; Mullin, Jillian K; Bradley, Corey A; Borthakur, Gautam; Maiti, Abhishek; Alvarado, Yesid; Pemmaraju, Naveen; Abbas, Hussein A; Hammond, Danielle E; Haddad, Fadi; Bravo, Guillermo Montalban; Chien, Kelly S; Yilmaz, Musa; Kornblau, Steven M; Jabbour, Elias; Ravandi, Farhad; Kadia, Tapan; Garcia-Manero, Guillermo; Konopleva, Marina Y; Kantarjian, Hagop M

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab

一线接受帕纳替尼和布林妥莫单抗治疗后,Ph+ ALL 患者的分子特征及复发预测因子

Short, Nicholas J; Kantarjian, Hagop; Furudate, Ken; Jain, Nitin; Ravandi, Farhad; Karrar, Omer; Loghavi, Sanam; Nasr, Lewis; Haddad, Fadi G; Senapati, Jayastu; Garris, Rebecca; Takahashi, Koichi; Jabbour, Elias

A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias

DS-1594 menin抑制剂治疗复发/难治性急性白血病的1/2期研究

Senapati, Jayastu; Konopleva, Marina; Issa, Ghayas C; Jabbour, Elias; Kadia, Tapan; DiNardo, Courtney; Borthakur, Gautam; Pemmaraju, Naveen; Short, Nicholas J; Yilmaz, Musa; Deshmukh, Indraneel; Alvarez, Joie; Loghavi, Sanam; Tang, Guilin; Abbas, Hussein A; Andreeff, Michael; Bhalla, Kapil; Midde, Narasimha M; Said, Nabil; Noyalis, Amy; Mires, Derek E; Ning, Jing; Xiao, Lianchun; Ravandi, Farhad; Garcia-Manero, Guillermo; Kantarjian, Hagop M; Daver, Naval G

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

降低MDS患者参与临床试验的门槛:icMDS立场声明

Borate, Uma; Pugh, Kelly; Waller, Allyson; Welkie, Rina Li; Huang, Ying; Bewersdorf, Jan Philipp; Stahl, Maximilian; DeZern, Amy E; Platzbecker, Uwe; Sekeres, Mikkael A; Wei, Andrew H; Buckstein, Rena J; Roboz, Gail J; Savona, Michael R; Loghavi, Sanam; Hasserjian, Robert P; Fenaux, Pierre; Sallman, David A; Hourigan, Christopher S; Della Porta, Matteo Giovanni; Nimer, Stephen; Little, Richard F; Santini, Valeria; Efficace, Fabio; Taylor, Justin; Garcia-Manero, Guillermo; Odenike, Olatoyosi; Kim, Tae Kon; Halene, Stephanie; Komrokji, Rami S; Griffiths, Elizabeth A; Greenberg, Peter L; Xu, Mina L; Xie, Zhuoer; Bejar, Rafael; Sanz, Guillermo F; Patnaik, Mrinal M; Figueroa, Maria; Carraway, Hetty E; Abdel-Wahab, Omar; Starczynowski, Daniel; Padron, Eric; Boultwood, Jacqueline; Gore, Steven; Daver, Naval G; Churpek, Jane E; Majeti, Ravindra; Bennett, John M; List, Alan F; Brunner, Andrew M; Zeidan, Amer M

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

CDK7抑制剂联合疗法对转化为AML的骨髓增生性肿瘤的临床前疗效

Fiskus Warren, Mill Christopher P, Bose Prithviraj, Masarova Lucia, Pemmaraju Naveen, Dunbar Andrew, Birdwell Christine E, Davis John A, Das Kaberi, Hou Hanxi, Manshouri Taghi, Jain Antrix, Malovannaya Anna, Philip Kevin, Alhamadani Noor, Matthews Alicia, Lin Katie, Flores Lauren B, Loghavi Sanam, DiNardo Courtney, Su Xiaoping, Rampal Raajit K, Bhalla Kapil N

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.

对 IDH 突变型急性髓系白血病中的克隆和细胞结构进行解卷积。

Sirenko Maria, Lee Soobeom, Sun Zhengxi, Chaligne Ronan, Loghavi Sanam, Asimomitis Georgios, Brierley Charlotte K, Bernard Elsa, Cai Sheng F, Myers Robert M, Nadorp Bettina, Sango Junya, Lallo Morgan, Levine Max F, Domenico Dylan, Arango Ossa Juan E, Medina-Martinez Juan S, Menghrajani Kamal, Lasry Audrey, Mims Alice S, Desai Helee, Laganson Andrea, Famulare Chris, Patel Minal, Lozanski Gerard, Bolton Kelly L, Viny Aaron D, Roshal Mikhail, Levine Ross L, Papapetrou Eirini P, Stein Eytan M, Landau Dan A, Eisfeld Ann-Kathrin, Aifantis Iannis, Papaemmanuil Elli